Investigational drug · Phase 3
Camrelizumab
Also called: SHR-1210, CAM
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
597
Any phase or sponsor naming "Camrelizumab"
First trial start
2020
Sep 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Camrelizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- HCC
- Non-squamous Non-small Cell Lung Cancer
- Hepatocellular Carcinoma
- Metastatic Pancreatic Cancer
- Non Squamous Non Small Cell Lung Cancer
- Gastric Cancer
- Hepatocellular Carcinoma (HCC)
- Recurrent or Metastatic Cervical Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Camrelizumab" as an intervention, largest first.
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)Recruiting
Qun ZhaoAcademic, hospital or other
NCT07401199 · 2,000 participants (planned) · Start Feb 5, 2026 · Primary completion Dec 30, 2027
Drug: Standard of Care PD-1 Inhibitors · For: Gastric Cancer (GC); Locally Advanced Gastric Cancer
Sites: Fuyang, China; Cangzhou, China; Hengshui, China · 9 sites in all
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruiting
Xuhua DuanAcademic, hospital or other
NCT07156617 · 2,000 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 1, 2027
Drug: Systemic therapy · For: Hepatocellular Carcinoma (HCC)
Sites: Haikou, China; Xingtai, China; Dengzhou, China · 14 sites in all
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06119347 · 1,581 participants · Start Jan 1, 2020 · Primary completion Jun 30, 2023
Drug: AntiVEGF; ICIs · For: AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Sites: Wenzhou, China
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
- A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical CancerNot yet recruiting
Qi ZhouAcademic, hospital or other
NCT07266350 · 1,300 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 30, 2028
Drug: Camrelizumab; Famitinib · For: Cervical Cancer Metastatic; Cervical Cancer Recurrent
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompleted
Zhongda HospitalAcademic, hospital or other
NCT05332821 · 1,244 participants · Start Dec 28, 2022 · Primary completion Jul 30, 2023
Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab · For: Hepatocellular Carcinoma
Sites: Nanjing, China; Shanghai, China
- A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal CancerNot yet recruiting
Peking UniversityAcademic, hospital or other
NCT04616040 · 1,030 participants (planned) · Start Dec 1, 2020 · Primary completion Dec 1, 2023
Drug: Camrelizumab · For: Esophageal Cancer
Sites: Beijing, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT04947956 · 1,000 participants (planned) · Start Sep 1, 2021 · Primary completion Sep 1, 2023
Drug: Camrelizumab · For: Unresectable Hepatocellular Carcinoma
Guangdong Association of Clinical TrialsAcademic, hospital or other
NCT04793139 · 1,000 participants (planned) · Start Apr 1, 2021 · Primary completion Jun 30, 2024
Drug: Camrelizumab · For: Non-small Cell Lung Cancer
- A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruiting
Harbin Medical UniversityAcademic, hospital or other
NCT07645209 · 1,000 participants (planned) · Start May 13, 2026 · Primary completion May 13, 2028
Drug: Immune Checkpoint Inhibitors · For: Liver Cancer
Sites: Harbin, China
Newest research
PubMed records naming it or its code names, newest first.
- Prototype-Guided Test-Time Adaptation for Real-Time EMG-Based Gesture Recognition.
Ma Y, Wang Y, Dai C, et al. · Int J Neural Syst 2027
- Knowledge-guided multi-objective deep learning enables robust LIBS analysis for industrial magnesium alloy identification.
Gao Z, Liu P, Wei Y, et al. · Talanta 2027
- Substituent-controlled optical and electronic properties of arylidene Rhodanines: Single-crystal structures, thin-film band gaps, and DFT/TD-DFT analysis.
Hagar E, Ayan E, Mermer A, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Shared-reference analysis of pathway-dependent excited-state responses in donor-side and terminal-side substituted phenyl-thiophene chromophores.
Albaqami MD · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Investigating non-reproducible high-sensitivity cardiac troponin T results in real-world practice.
Evren ZŞ, Uçar KT · Clin Chim Acta 2027
- CDK4/6 inhibition suppresses mTOR activity and growth in lymphangioleiomyomatosis (LAM).
Kundu N, Fard SS, Di Martino JS, et al. · Biochim Biophys Acta Mol Basis Dis 2027
Also in development for HCC
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- tirapazaminePhase 32 trials
Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- GNOS-PV02Phase 22 trials
Geneos Therapeutics · HCC
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- PM1009Phase 21 trial
Biotheus Inc. · HCC, Liver Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.